Concepts (286)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Sickle Cell | 42 | 2024 | 183 | 7.370 |
Why?
|
| Hydroxyurea | 7 | 2015 | 34 | 1.350 |
Why?
|
| Antisickling Agents | 6 | 2015 | 15 | 1.300 |
Why?
|
| Hypertension, Pulmonary | 11 | 2017 | 75 | 1.270 |
Why?
|
| Pain | 6 | 2023 | 251 | 1.070 |
Why?
|
| Fetal Hemoglobin | 5 | 2017 | 14 | 0.980 |
Why?
|
| Vascular Diseases | 3 | 2014 | 30 | 0.910 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2014 | 628 | 0.680 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2014 | 767 | 0.650 |
Why?
|
| Pain Threshold | 1 | 2017 | 28 | 0.610 |
Why?
|
| Haplotypes | 4 | 2014 | 182 | 0.600 |
Why?
|
| Adult | 32 | 2024 | 11712 | 0.570 |
Why?
|
| Cardiovascular Diseases | 2 | 2013 | 664 | 0.550 |
Why?
|
| Humans | 53 | 2024 | 37093 | 0.530 |
Why?
|
| Hemolysis | 6 | 2014 | 40 | 0.500 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2023 | 169 | 0.490 |
Why?
|
| GTP Cyclohydrolase | 1 | 2014 | 4 | 0.480 |
Why?
|
| Mutation | 5 | 2013 | 1095 | 0.480 |
Why?
|
| Male | 30 | 2024 | 20025 | 0.460 |
Why?
|
| Lipoproteins | 2 | 2013 | 64 | 0.450 |
Why?
|
| Female | 31 | 2024 | 20969 | 0.450 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2013 | 26 | 0.430 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2011 | 30 | 0.400 |
Why?
|
| Middle Aged | 18 | 2024 | 10129 | 0.360 |
Why?
|
| Rhabdomyosarcoma | 1 | 2009 | 1 | 0.360 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 4 | 1 | 2009 | 2 | 0.360 |
Why?
|
| Hematologic Diseases | 1 | 2009 | 14 | 0.350 |
Why?
|
| Polymorphism, Genetic | 2 | 2008 | 191 | 0.340 |
Why?
|
| Hemoglobins | 2 | 2011 | 107 | 0.320 |
Why?
|
| Stroke | 2 | 2002 | 286 | 0.320 |
Why?
|
| Genetic Markers | 3 | 2014 | 142 | 0.310 |
Why?
|
| Depression | 1 | 2014 | 712 | 0.310 |
Why?
|
| Proportional Hazards Models | 5 | 2015 | 441 | 0.300 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 2 | 2007 | 28 | 0.290 |
Why?
|
| Adolescent | 14 | 2021 | 5363 | 0.290 |
Why?
|
| Alleles | 4 | 2014 | 321 | 0.280 |
Why?
|
| Young Adult | 10 | 2021 | 4268 | 0.270 |
Why?
|
| Anemia, Aplastic | 2 | 2016 | 2 | 0.270 |
Why?
|
| Tricuspid Valve Insufficiency | 4 | 2020 | 12 | 0.260 |
Why?
|
| Genetic Variation | 3 | 2014 | 387 | 0.250 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2016 | 159 | 0.250 |
Why?
|
| Iron | 3 | 2014 | 225 | 0.240 |
Why?
|
| Proteinuria | 1 | 2024 | 50 | 0.240 |
Why?
|
| Cohort Studies | 6 | 2014 | 1492 | 0.230 |
Why?
|
| Mannose-Binding Lectin | 2 | 2005 | 5 | 0.230 |
Why?
|
| Pyrazoles | 1 | 2024 | 85 | 0.230 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2023 | 10 | 0.230 |
Why?
|
| Prospective Studies | 6 | 2020 | 1378 | 0.220 |
Why?
|
| alpha-Thalassemia | 3 | 2014 | 4 | 0.220 |
Why?
|
| Prevalence | 3 | 2018 | 1455 | 0.220 |
Why?
|
| Hemoglobinopathies | 1 | 2023 | 5 | 0.220 |
Why?
|
| Pyrimidines | 1 | 2024 | 118 | 0.220 |
Why?
|
| Receptors, IgG | 2 | 2005 | 50 | 0.220 |
Why?
|
| Volatile Organic Compounds | 1 | 2023 | 17 | 0.220 |
Why?
|
| Thrombophilia | 1 | 2002 | 4 | 0.220 |
Why?
|
| Aged | 9 | 2021 | 6741 | 0.210 |
Why?
|
| Case-Control Studies | 5 | 2021 | 1130 | 0.210 |
Why?
|
| Risk Factors | 8 | 2014 | 3562 | 0.210 |
Why?
|
| Treatment Outcome | 5 | 2024 | 1369 | 0.210 |
Why?
|
| Sickle Cell Trait | 1 | 2021 | 17 | 0.200 |
Why?
|
| Adjuvants, Immunologic | 1 | 2002 | 107 | 0.200 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2021 | 15 | 0.200 |
Why?
|
| Promoter Regions, Genetic | 5 | 2014 | 515 | 0.190 |
Why?
|
| Gene Frequency | 3 | 2014 | 195 | 0.190 |
Why?
|
| Hypertension | 2 | 2024 | 796 | 0.190 |
Why?
|
| Gene Expression Regulation | 3 | 2015 | 1015 | 0.190 |
Why?
|
| Child | 9 | 2023 | 3131 | 0.180 |
Why?
|
| Ferritins | 3 | 2020 | 55 | 0.180 |
Why?
|
| Orosomucoid | 1 | 2020 | 12 | 0.180 |
Why?
|
| Leg Ulcer | 2 | 2011 | 8 | 0.180 |
Why?
|
| Gene Expression Profiling | 2 | 2015 | 626 | 0.180 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 239 | 0.170 |
Why?
|
| Thalassemia | 2 | 2009 | 3 | 0.170 |
Why?
|
| Hospitals, Special | 1 | 2018 | 3 | 0.170 |
Why?
|
| United States | 7 | 2020 | 4223 | 0.170 |
Why?
|
| Congo | 1 | 2018 | 3 | 0.170 |
Why?
|
| Patient Care | 1 | 2018 | 29 | 0.160 |
Why?
|
| Phenotype | 2 | 2014 | 689 | 0.160 |
Why?
|
| Survival Rate | 4 | 2020 | 311 | 0.160 |
Why?
|
| Bacteria | 1 | 2021 | 255 | 0.160 |
Why?
|
| Biomedical Research | 2 | 2013 | 400 | 0.160 |
Why?
|
| Touch | 1 | 2017 | 19 | 0.150 |
Why?
|
| Hyperalgesia | 1 | 2017 | 18 | 0.150 |
Why?
|
| Odds Ratio | 2 | 2014 | 534 | 0.150 |
Why?
|
| Cold Temperature | 1 | 2017 | 40 | 0.150 |
Why?
|
| Echocardiography | 3 | 2017 | 144 | 0.150 |
Why?
|
| Hematopoiesis | 2 | 2014 | 28 | 0.150 |
Why?
|
| Erythroid Cells | 2 | 2014 | 6 | 0.150 |
Why?
|
| Epoprostenol | 1 | 2017 | 25 | 0.150 |
Why?
|
| Hot Temperature | 1 | 2017 | 128 | 0.140 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2016 | 259 | 0.140 |
Why?
|
| Precursor Cells, T-Lymphoid | 1 | 2016 | 1 | 0.140 |
Why?
|
| Cholesterol, HDL | 2 | 2013 | 97 | 0.140 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 9 | 0.140 |
Why?
|
| Hematocrit | 2 | 2013 | 18 | 0.140 |
Why?
|
| HIV-1 | 1 | 2021 | 706 | 0.130 |
Why?
|
| Immunologic Memory | 1 | 2016 | 38 | 0.130 |
Why?
|
| Protein Structure, Tertiary | 2 | 2009 | 408 | 0.130 |
Why?
|
| Pregnancy Proteins | 1 | 2014 | 4 | 0.120 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2014 | 22 | 0.120 |
Why?
|
| Biological Clocks | 1 | 2014 | 53 | 0.120 |
Why?
|
| Plethysmography | 1 | 2014 | 6 | 0.120 |
Why?
|
| Endothelium | 1 | 2014 | 31 | 0.120 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 284 | 0.120 |
Why?
|
| Heme | 1 | 2014 | 70 | 0.120 |
Why?
|
| Leukemia | 2 | 2005 | 56 | 0.120 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 974 | 0.120 |
Why?
|
| Logistic Models | 2 | 2013 | 923 | 0.120 |
Why?
|
| Candidiasis | 2 | 2005 | 84 | 0.110 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 114 | 0.110 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2014 | 253 | 0.110 |
Why?
|
| Genotype | 3 | 2012 | 730 | 0.110 |
Why?
|
| Base Sequence | 2 | 2013 | 997 | 0.110 |
Why?
|
| Double-Blind Method | 2 | 2024 | 286 | 0.110 |
Why?
|
| Suicide | 1 | 2014 | 118 | 0.110 |
Why?
|
| Mutant Proteins | 1 | 2012 | 51 | 0.110 |
Why?
|
| Sleep | 1 | 2014 | 152 | 0.110 |
Why?
|
| Cation Transport Proteins | 1 | 2012 | 34 | 0.110 |
Why?
|
| Hospitalization | 1 | 2015 | 388 | 0.100 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2011 | 62 | 0.100 |
Why?
|
| Genome, Human | 1 | 2013 | 135 | 0.100 |
Why?
|
| Comorbidity | 1 | 2014 | 623 | 0.100 |
Why?
|
| Cell Differentiation | 2 | 2014 | 587 | 0.100 |
Why?
|
| Exercise Tolerance | 1 | 2011 | 15 | 0.100 |
Why?
|
| Homozygote | 3 | 2011 | 77 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 2 | 2011 | 474 | 0.100 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2011 | 43 | 0.100 |
Why?
|
| Alternative Splicing | 1 | 2011 | 85 | 0.100 |
Why?
|
| Severity of Illness Index | 4 | 2015 | 610 | 0.100 |
Why?
|
| Cell Lineage | 1 | 2011 | 90 | 0.090 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2008 | 88 | 0.090 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2011 | 85 | 0.090 |
Why?
|
| Sex Factors | 1 | 2014 | 898 | 0.090 |
Why?
|
| Quality of Life | 1 | 2014 | 481 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2015 | 426 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2015 | 481 | 0.090 |
Why?
|
| DNA | 1 | 2013 | 574 | 0.090 |
Why?
|
| Transplantation, Heterologous | 1 | 2009 | 90 | 0.090 |
Why?
|
| Retrospective Studies | 1 | 2015 | 2026 | 0.090 |
Why?
|
| Cell Line, Transformed | 1 | 2009 | 91 | 0.090 |
Why?
|
| Inflammation | 2 | 2014 | 618 | 0.080 |
Why?
|
| Kidney Diseases | 2 | 2008 | 167 | 0.080 |
Why?
|
| STAT3 Transcription Factor | 1 | 2009 | 90 | 0.080 |
Why?
|
| DNA Replication | 1 | 2009 | 152 | 0.080 |
Why?
|
| Lipids | 1 | 2010 | 235 | 0.080 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2008 | 7 | 0.080 |
Why?
|
| Neoplasm Metastasis | 1 | 2009 | 219 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2008 | 15 | 0.080 |
Why?
|
| False Positive Reactions | 1 | 2008 | 26 | 0.080 |
Why?
|
| Mice | 3 | 2021 | 5913 | 0.080 |
Why?
|
| Cell Cycle | 1 | 2009 | 326 | 0.080 |
Why?
|
| HIV Infections | 1 | 2021 | 2303 | 0.080 |
Why?
|
| Arginine | 1 | 2008 | 73 | 0.080 |
Why?
|
| Brain | 1 | 2015 | 1346 | 0.080 |
Why?
|
| Ultrasonography | 1 | 2008 | 112 | 0.080 |
Why?
|
| Nitric Oxide Synthase | 1 | 2008 | 128 | 0.070 |
Why?
|
| Age Distribution | 1 | 2008 | 225 | 0.070 |
Why?
|
| Nitric Oxide | 1 | 2009 | 316 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2008 | 325 | 0.070 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2021 | 234 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2015 | 661 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 214 | 0.070 |
Why?
|
| Phosphorylation | 1 | 2009 | 928 | 0.070 |
Why?
|
| Erythropoietin | 1 | 2006 | 39 | 0.070 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 2721 | 0.070 |
Why?
|
| Child, Preschool | 3 | 2020 | 1418 | 0.070 |
Why?
|
| Animals | 4 | 2021 | 15081 | 0.070 |
Why?
|
| Models, Molecular | 1 | 2009 | 808 | 0.070 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2008 | 421 | 0.070 |
Why?
|
| Lung Neoplasms | 1 | 2009 | 358 | 0.060 |
Why?
|
| Leukocyte Count | 2 | 2020 | 77 | 0.060 |
Why?
|
| Organic Anion Transporters, Sodium-Dependent | 1 | 2004 | 1 | 0.060 |
Why?
|
| Lymphocyte Activation | 2 | 2016 | 236 | 0.060 |
Why?
|
| Symporters | 1 | 2004 | 11 | 0.060 |
Why?
|
| Immunity, Innate | 1 | 2005 | 149 | 0.060 |
Why?
|
| Genomics | 2 | 2004 | 223 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 1371 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2009 | 485 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2009 | 1198 | 0.060 |
Why?
|
| Models, Biological | 1 | 2007 | 677 | 0.060 |
Why?
|
| Disease Progression | 2 | 2021 | 601 | 0.060 |
Why?
|
| Iron Overload | 2 | 2014 | 8 | 0.060 |
Why?
|
| E-Selectin | 1 | 2023 | 21 | 0.060 |
Why?
|
| Interleukin-4 | 1 | 2003 | 72 | 0.060 |
Why?
|
| Cell Line, Tumor | 1 | 2009 | 2231 | 0.050 |
Why?
|
| Jamaica | 1 | 2002 | 11 | 0.050 |
Why?
|
| Codon | 1 | 2002 | 42 | 0.050 |
Why?
|
| Open Reading Frames | 1 | 2002 | 77 | 0.050 |
Why?
|
| Introns | 1 | 2002 | 75 | 0.050 |
Why?
|
| Amino Acid Substitution | 1 | 2002 | 132 | 0.050 |
Why?
|
| DNA, Complementary | 1 | 2002 | 191 | 0.050 |
Why?
|
| Kringles | 1 | 2021 | 5 | 0.050 |
Why?
|
| Blood Pressure | 2 | 2017 | 646 | 0.050 |
Why?
|
| Early Diagnosis | 1 | 2021 | 64 | 0.050 |
Why?
|
| Phylogeny | 1 | 2004 | 644 | 0.050 |
Why?
|
| Analgesics, Opioid | 1 | 2023 | 197 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 1 | 2021 | 139 | 0.050 |
Why?
|
| Cluster Analysis | 2 | 2011 | 195 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 113 | 0.040 |
Why?
|
| Models, Genetic | 2 | 2014 | 172 | 0.040 |
Why?
|
| Time Factors | 2 | 2014 | 1742 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2023 | 1908 | 0.040 |
Why?
|
| Neutrophils | 1 | 2020 | 131 | 0.040 |
Why?
|
| Prognosis | 1 | 2021 | 739 | 0.040 |
Why?
|
| Acute Disease | 2 | 2011 | 147 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2014 | 1207 | 0.040 |
Why?
|
| Age Factors | 2 | 2011 | 1033 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2017 | 91 | 0.040 |
Why?
|
| Uveitis | 1 | 2016 | 5 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2016 | 46 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2016 | 64 | 0.030 |
Why?
|
| Rest | 1 | 2015 | 26 | 0.030 |
Why?
|
| Autoimmune Diseases | 1 | 2016 | 57 | 0.030 |
Why?
|
| Recurrence | 1 | 2016 | 131 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 2016 | 89 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 88 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2014 | 14 | 0.030 |
Why?
|
| Neural Pathways | 1 | 2015 | 124 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2015 | 112 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2016 | 250 | 0.030 |
Why?
|
| Hemin | 1 | 2014 | 6 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2014 | 17 | 0.030 |
Why?
|
| K562 Cells | 1 | 2014 | 32 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2014 | 61 | 0.030 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2016 | 155 | 0.030 |
Why?
|
| alpha-Globins | 1 | 2014 | 4 | 0.030 |
Why?
|
| Creatinine | 1 | 2014 | 103 | 0.030 |
Why?
|
| Walking | 1 | 2014 | 68 | 0.030 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2013 | 7 | 0.030 |
Why?
|
| Mortality | 1 | 2014 | 145 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2014 | 166 | 0.030 |
Why?
|
| Echocardiography, Doppler | 1 | 2013 | 37 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2012 | 27 | 0.030 |
Why?
|
| Registries | 1 | 2014 | 335 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2012 | 42 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2014 | 308 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 204 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2011 | 19 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2012 | 295 | 0.020 |
Why?
|
| Pulmonary Artery | 1 | 2011 | 31 | 0.020 |
Why?
|
| Hemoglobin, Sickle | 1 | 2011 | 13 | 0.020 |
Why?
|
| Exercise Test | 1 | 2011 | 67 | 0.020 |
Why?
|
| Exons | 1 | 2011 | 88 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2011 | 89 | 0.020 |
Why?
|
| Uric Acid | 1 | 2011 | 26 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2014 | 933 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2011 | 93 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2005 | 484 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2011 | 120 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 400 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 306 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2013 | 753 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 399 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 448 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 583 | 0.020 |
Why?
|
| Triglycerides | 1 | 2010 | 138 | 0.020 |
Why?
|
| Gene Expression | 1 | 2012 | 674 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2011 | 333 | 0.020 |
Why?
|
| Macrophages | 1 | 2012 | 439 | 0.020 |
Why?
|
| Cell Line | 1 | 2012 | 1354 | 0.020 |
Why?
|
| Cholesterol | 1 | 2010 | 205 | 0.020 |
Why?
|
| omega-N-Methylarginine | 1 | 2008 | 4 | 0.020 |
Why?
|
| Citrulline | 1 | 2008 | 10 | 0.020 |
Why?
|
| Creatine | 1 | 2008 | 8 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2010 | 237 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 935 | 0.020 |
Why?
|
| Mitogens | 1 | 2007 | 10 | 0.020 |
Why?
|
| Platelet Count | 1 | 2007 | 13 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2007 | 79 | 0.020 |
Why?
|
| Risk | 1 | 2008 | 267 | 0.020 |
Why?
|
| Linear Models | 1 | 2008 | 275 | 0.020 |
Why?
|
| Leukocytes | 1 | 2007 | 72 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2011 | 854 | 0.020 |
Why?
|
| Oxygen | 1 | 2008 | 207 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2007 | 77 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2006 | 227 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2008 | 894 | 0.020 |
Why?
|
| Gene Components | 1 | 2004 | 2 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2006 | 515 | 0.020 |
Why?
|
| Base Composition | 1 | 2004 | 23 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2004 | 59 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2004 | 85 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 578 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 1568 | 0.010 |
Why?
|
| Species Specificity | 1 | 2004 | 245 | 0.010 |
Why?
|
| Candida | 1 | 2003 | 40 | 0.010 |
Why?
|